Form 4 for DCOY Decoy Therapeutics Inc.
Accepted 2022-03-09 00:00:00 ET · period of report 2022-03-03 · accession 0001615219-22-000019 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-03-09 | 2022-03-03 | DCOY | Rosenblum Mark J | CFO, EVP Fin | P - Purchase | $0.39 | +76.2K | 110.3K | +224% | +$29.7K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-03-03 | P | A | 76,246 | $0.39 | 110,319 | D | — | — | (F1) The Registrant issued these shares to the reporting person as part of his bonus; which shares were issued in lieu of net cash compensation. The shares were issued at the fair market value of the Registrants common stock on the date of grant. |